Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

This research is being done to find out if an investigational drug, Nivolumab, can be safely administered after a "half-matched" (haplo) bone marrow transplant (BMT), and if the investigational drug will help to prevent or delay relapse or progression of sarcomas. In this study investigators will also be trying to learn more about how the investigational drug changes blood and/or tumors. Participants are eligible for this trial if they have recently undergone a "half-matched" (haplo) bone marrow transplant and have either relapsed or are at high risk to relapse.

Trial Details

NCT ID
NCT03465592
Phase
PHASE1 / PHASE2
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Nivolumab
Locations (sample)
  • St. Petersburg, Florida, United States|27.77086,-82.67927
  • Baltimore, Maryland, United States|39.29038,-76.61219
  • The Bronx, New York, United States|40.84985,-73.86641
  • Valhalla, New York, United States|41.07482,-73.77513

Key Eligibility Criteria

  • Patients must be ≥ 12 months and ≤ 50 years of age at the time of study enrollment.
  • Patients with histologically confirmed solid tumors with an estimated poor long term survival.
  • Performance Level: Karnofsky ≥ 50% for patients \> 16 years of age and Lansky ≥ 60 for patients ≤16 years of age.
  • Patients must be post RIC haploidentical BMT.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →